Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Pain
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 259207
MAY-44 is a non-estrogen topical analgesic gel containing a patented pH-balanced formulation of 3.75% lidocaine and other essential excipients designed for use on mucosal surfaces. If FDA-approved, MAY-44 could become the first topical non-estrogen-based product indicated for this large underserved medical need. Anecdotal evidence has shown topical lidocaine, which only needs to be applied immediately prior to intercourse, can be highly effective (90%) for moderate to severe dyspareunia.
Dyspareunia is the term for recurring pain in the genital area or within the pelvis during sexual intercourse. The pain can be sharp or intense. It can occur before, during, or after sexual intercourse. Dyspareunia is more common in women than men.
IPSCIO Record ID: 258698
IPSCIO Record ID: 310525
For the Option for additional Territories of Canada and Mexico, Licensor grants an option to extend this Agreement to cover a sole and exclusive, license, on royalty terms that are substantially similar to those set forth in this Agreement, with the right to sublicense, to the Intellectual Property Rights including the right to develop, use, market, promote, and sell Product in Canada and Mexico.
For the Trademark License Grant, Licensor grants an exclusive right and license, to use the Trademark in connection with the marketing, promotion, advertising, and sale or other distribution of the Product in the Territory.
For the Submission Package, Licensor grants an option for a sole and exclusive license, with the right to sublicense, to the Intellectual Property Rights including the right to develop, use, market, promote, and sell a topical formulation of lidocaine in a gel formulation (Development Product), whether sold over-the-counter or by prescription, for human use which falls within the claims of the Licensed Patents.
If Licensee exercises its option, the parties agree to license such Intellectual Property Rights on terms to be mutually agreed to by the parties.based substantially on the terms of this Agreement.
The Patents are titled Method for Treating Nerve Injury Pain Associated with Shingles; Method for Treating Nerve Injury Pain Associated with Shingles Herpes-Zoster and Post-Herpetic Neuralgia) by Topical Application Of Lidocaine; Method for Treating Pain Associated with Herpes Zoster and Post-Herpetic Neuralgia; and, Method for Treating Nerve Injury Pain Associated with Shingles (Herpes-zoster and Post Herpetic Neuralgia) by Topical Application of Lidocaine.
Product means any topical formulation of lidocaine in a bandage and/or transdermal (Patch) formulation, whether sold over-the counter or by prescription, for human use which falls within the claims of the Licensed Patents.
Trademark shall mean the trademarks LIDODERM or TAKON that may be used to market the Product in the Territory.
Lidocaine patches are used to relieve the pain of post-herpetic neuralgia (PHN; the burning, stabbing pains, or aches that may last for months or years after a shingles infection). Lidocaine is in a class of medications called local anesthetics. It works by stopping nerves from sending pain signals.
Lidoderm(R) (Lidocaine Patch 5%) is a transdermal pharmaceutical patch product for the treatment of post-herpetic neuralgia.
Postherpetic neuralgia is the most common complication of shingles. The condition affects nerve fibers and skin, causing burning pain that lasts long after the rash and blisters of shingles disappear. The chickenpox (herpes zoster) virus causes shingles.
Licensee is a pharmaceutical company engaged in research, development, and marketing of various products, including pain management products.
